Residual genomic signature of atopic dermatitis despite clinical resolution with narrow-band UVB - 30/01/13
J.G.K. and M.S.-F. were supported by grant no. 5UL1RR024143-02 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. E.G.-Y. was supported by the Dermatology Foundation Physician Scientist Career Development Award. |
|
Disclosure of potential conflict of interest: J. G. Krueger has been a consultant for Janssen, Eli Lilly, and Pfizer; has received grants or has grants pending for anti-TNF from Amgen, anti-p40 and anti–IL-23 from Janssen, anti–IL-17 from Eli Lilly, anti–IL-23 from Merck, and CP690, 550 from Pfizer. E. Guttman-Yassky has received grants from the Dermatology Foundation, Regeneron, and Merck to the Mount Sinai School of Medicine and has been a consultant for Regeneron, Celgene, Merck, Pfizer, and Stiefel. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 131 - N° 2
P. 577-579 - février 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?